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Abstract While all features of the inflammatory response 
induced by IL-I are not observed following IL-4 stimulation, 
suboptimal concentrations both cytokines result in synergistic 
VCAM-1 expression in HUVEC. We have shown that, while IL-1 
stimulated HUVEC express GM-CSF, tissue factor and VCAM- 
1, only VCAM-1 is detectable after exposure to IL-4. While kB 
was found essential for both basal and IL-l-mediated activity of 
VCAM-I, IL-4 induction was kB-independent. Inducible kB- 
binding proteins were identified in IL-I-, but not IL-4-stimulated 
nuclear extracts. Our results indicate that IL-4 exerts its tran- 
scriptional effects on the VCAM-I gene through element(s) which 
do not require kB. 
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1. Introduction 
Endothelial cells undergo morphological and biochemical 
changes in response to diverse inflammatory stimuli. This in- 
flammatory phenotype involves the expression of multiple cy- 
tokines, coagulation and flbrinolytic factors and cytoadhesion 
molecules. Cytokines, such as IL-1, TNF-~ and IL-4, act on 
endothelium to give rise to functional sets of proteins which 
initiate and support he inflammatory response. While the sets 
of genes induced in endothelium by stimulation with either 
TNF-e, IL-1 or LPS are quite similar, treatment with IL-4 
results in a different response. For example, IL-4 downregu- 
lates a number of endothelial genes activated by either IL-1 or 
TNF-0~, including tissue factor [I], ICAM-1 [2] and E-selectin 
[3]. In addition, IL-4 acts in synergy with IL-1 or TNF-c~ to 
express MCP-1 [4], IL-6 [5,6] and VCAM-1 [7,8]. These findings 
suggest that IL-4 acts through endothelial mechanisms distinct 
from those induced by IL-I or TNF-~. 
An important aspect of the endothelial response to inflam- 
matory stimuli is the expression of VCAM-1 on the luminal 
surface. By providing a mechanism for adherence of lympho- 
cytes, monocytes and eosinophils, VCAM-1 serves to both 
establish and amplify the inflammatory process [3,7-12] 
VCAM- 1 is induced on endothelial surfaces by stimulation with 
LPS, IL-I, TNF-~ [13] or IL-4 [7,8,14]. Previous studies have 
*Corresponding author. Fax: (1) (206) 685-3062. 
Abbreviations: VCAM-1, vascular cell adhesion molecule-l; HUVEC, 
human umbilical vein endothelial cells; GM-CSF, granulocyte macro- 
phage colony-stimulating factor; MCP-1, monocyte chemotactic pro- 
tein-l; ICAM-1, intercellular adhesion molecule-l; ELISA, enzyme- 
linked immunosorption assay; EMSA, electrophoretic mobility shift 
assay. 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. 
SSDI  0014-5793(95)00976-0 
shown that, while the protein is expressed at the cell surface by 
4-6 h, peaks at 24 h and declines toward baseline after 72 h of 
stimulation by IL-1 or TNF-a [15], its expression after IL-4 
stimulation isdelayed. Thornhill [8] demonstrated induction of 
VCAM-1 expression o earlier than 12-14 h, with peak expres- 
sion at 24 h, depending on the concentration of 1L-4 used. 
Costimulation experiments performed by Thornhill [8] and 
Masinovsky [7] showed that submaximal levels ofIL-1 and IL-4 
synergistically induced the expression of VCAM-1 on HUVEC. 
Iademarco et al. [14] showed by flow cytometry (FACS) analy- 
sis of HUVEC stimulated by TNF-c~ and IL-4 that VCAM-1 
expression i creased to levels above that seen with either agent 
alone; in addition, the combination prolonged VCAM-1 pro- 
tein at the cell surface beyond that seen with TNF-a alone. 
Together, these observations suggest that separate but cooper- 
ative pathways exist for the transcriptional ctivation of the 
VCAM-I promoter by these cytokines. 
Initial reports by Iademarco [13,16] and Neish [17] have 
identified some of the elements required for the expression of 
VCAM-l in IL-1 and TNF-a-stimulated HUVEC. From these 
studies, octamer motifs, paired GATA sites and, perhaps most 
importantly, a pair of xB sequences were found to be essential 
for the transcriptional ctivation of the VCAM-l gene in re- 
sponse to IL-1 and TNF-c~. Particular attention has been paid 
to members of the c-rel family of transcription factors in the 
regulation of genes involved in the inflammatory response. 
Functional analysis of the promoters of the GM-CSF [18], 
tissue factor [19], M-CSF [20], IL-6 [21], E-selectin [22,23], 
ICAM- 1 [24] and VCAM- 1 [ 13,16,17] genes have demonstrated 
that NF-kB-binding sites are essential for the transcriptional 
regulation of these inflammatory mediators in endothelium, 
lymphocytes and monocytes. In contrast, little is known about 
the promoter elements required for IL-4-induced VCAM-1 ex- 
pression. 
In this paper, we report on the differential effects of IL-1 and 
IL-4 stimulation on the expression of VCAM-1 in HUVEC. 
Optimal concentrations of IL-1 and IL-4 for the induction of 
VCAM-1 protein were selected by a sensitive ELISA. In addi- 
tion, EL1SA and functional assays for GM-CSF and tissue 
factor were performed in order to determine whether IL-I and 
IL-4 also differentially regulated the expression of these endo- 
thelial cell proinflammatory proteins. Both IL-1 and IL-4 were 
found to induce VCAM-I, but in contrast o IL-1, neither 
GM-CSF nor tissue factor were induced at any concentration 
of IL-4. These results reinforce the assertion that the endothe- 
lial cell activation pathways for IL-I and IL-4 differ. Because 
the NF-xB complex has been found to be necessary for full 
expression of the VCAM-1 gene, we have focused on the func- 
tional role of these sequences in response to IL-4. Reporter 
All rights reserved. 
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~: ene analysis revealed that both constitutive and I L-1-mediated 
iaduction of VCAM-I  was dependent on xB. In contrast, 
I L-4-mediated induction of VCAM-1 was found to be inde- 
pendent of xB. This latter result was confirmed by EMSAs 
which demonstrated that, although xB-binding proteins could 
i,e detected in quiescent endothelial cell nuclei and their levels 
vere increased by IL-1 stimulation, nuclear translocation of 
qF-xB was not seen in response to IL-4 stimulation. Thus, IL-4 
~nduction of VCAM-1 represents a distinct activation mecha- 
f ism in HUVEC,  a finding which warrants further study. 
'.. Materials and methods 
'.1. ELISA of HUVEC 
Second passage HUVEC were grown to confluence using culture 
:onditions previously described [25] in duplicate gelatin-coated 96well 
)lares. After stimulation with cytokines, the supernatants were removed 
?ore each plate and assayed for GM-CSF by ELISA activity as previ- 
msly described [26]. One plate was assayed for VCAM-I by ELISA 
lsing mAb 4B9 as described [9]. The second plate was assayed for tissue 
"actor activity in the method escribed below. 
?.2. Procoagulant activity assay 
Tissue factor activity was assayed by the method of Suprenant [27]. 
Following stimulation with cytokines, HUVEC grown in 96 well plates 
:vere decanted of media and excess was blotted off with paper towels. 
100 ,ul of 0.02% saponin in medium was added to each well and incu- 
3ated at room temperature for 10 rain. After decanting the saponin- 
:ontaining medium, 50 pl of a mixture of 212 pg/ml S-222 (KBI Phar- 
rnacia, Franklin, OH) and 10 U/ml Factor VII-Proplex T solution, in 
HUVEC medium without phenol red was added, and allowed to incu- 
bate at 37°C for 2 h. The activity was read using a Biokinetic plate 
I reader (Biotek Instruments, Winsooki, VT) at 405nm at 1 and 2 h. 
2.3. Reporter gene assay 
Reporter gene constructs were assembled by linking the proximal 504 
bp upstream of the ATG site of the VCAM-1 gene to chloramphenicol 
acetyl transferase (CAT) as a reporter gene. Construct WTCAT 
contains the wild-type promoter sequences; the NF-xB consensus 
binding sequences have been substituted with random sequences (-79 
CTCTATGACCTCAATTGCTCTGCAGTTCTCCGCCTCTGCCT- 
CCG -49) in xB/zCAT. After transfection i to cultured HUVEC by 
electroporation, reporter gene assays were performed as previously 
described [28]. 
2.4. EMSA 
Using nuclear extracts from IL-1- and IL-4-stimulated HUVEC pre- 
pared in the manner described by Dignam [29], EMSA were performed 
using duplex oligonucleotides containing the xB consensus binding 
sequences from VCAM-1 (AATTCCCTGGTTTCCCCTTGAAGG- 
GATTTCCCTCC) and from the human immunoglobulin Igx enhancer 
(AATTTCCCCAGAGGGGGATTTCCAAGAGGCC) as previously 
described [30]. 
2.5. Reagents 
The 1L-I and IL-4 used in this study were generous gilts of S. Gillis 
(Immunex, Seattle, WA). Anti-VCAM-1 monoclonal antibodies were 
prepared as described [9]. 
3. Results 
3.1. IL-4 induces VCAM-1 protein 
As shown in Fig. 1, IL-1 induced endothelial cell expression 
of VCAM-1, GM-CSF and tissue factor in a concentration- 
dependent manner. In contrast, IL-4 induced VCAM-1, but not 
GM-CSF or tissue factor. A difference in the time course of 
IL-1- and I L-4-induced VCAM-1 expression was also apparent. 
VCAM-1 was induced by IL-1 within 4 h and declined after 24 
h. In contrast, while IL-4 induction of VCAM-1 was also de- 
tectable within 4 h, expression continued to increase at 48 h. 
3.2. Functional assessment of  VCAM-I  promoter activity 
Reporter gene assays were performed to evaluate the relative 
functional contribution of xB sequences in the regulation of 
VCAM-1 expression. The WTCAT construct was chosen for 
study as it contains the two xB sites and in preliminary exper- 
iments was found to be a highly active reporter, a finding 
consistent with that of Iademarco [16] and Neish [17]. A mutant 
construct in which the xB motifs were altered to random se- 
quences, xB/ICAT, was used to test the contribution of tcB to 
IL-1 and IL-4 induction of VCAM-I .  As shown in Table 1, 
stimulation of the WTCAT construct by either IL-I or IL-4 
resulted in a 1A~2.4-fold induction in CAT expression. Com- 
pared with the wild-type vector, constitutive reporter gene ac- 
tivity of the xB/ICAT construct was substantially reduced. 
However, despite this lower baseline activity, culture with IL-4, 
but not with IL-1, resulted in a 2-3-fold induction of reporter 
gene activity. While differences in reporter gene activity be- 
tween the two constructs were seen up to 48 h after stimulation, 
the most marked difference was observed at 24 h. 
3.3. EMSA demonstrates no IL-4-inducible rob-binding proteins 
In order to confirm our results with the reporter gene assays, 
we next performed EMSAs using oligonucleotide probes con- 
Table 1 
Relative CAT activity of the VCAM-1 promoter comparing WTCAT and xB/~CAT constructs 
24 h 48 h 
Fold induction S.E.M. Fold induction S.E.M. 
WTCAT 
None (1.00) 
IL-I 0.5 U/ml 1.57 
IL-1 20 U/ml 2.00 
IL-4 500 U/ml 1.92 
IL-4 5000 U/ml 2.32 
I¢B/~ CAT 
None 0.26 
IL-1 0.5 U/ml 0.26 
IL-I 20 U/ml 0.13 
IL-4 500 U/ml 0.83 
IL-4 5000 U/ml 0.63 
(0.00) (l.OO) (0.00) 
0.14 2.40 0.01 
0.00 1.43 0.10 
0.25 1.59 0.02 
0.13 1.36 0.13 
(1.00) 0.06 0.38 (1.00) 0.11 
1.00 0.06 0.46 1.21 0.05 
0.50 0.00 0.39 1.00 0.11 
3.20 0.15 0.79 2.07 0.05 
2.42 0.17 0.24 1.58 0.05 
Results are reported as fold induction relative to unstimulated WTCAT (data columns 1 and 4) or to unstimulated xB/tCAT (data columns 2 and 
5). S.E.M. of nine experiments reported in data columns 3 and 6. 
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Fig. 1. Induction of tissue factor, GM-CSF and VCAM-1 by IL-1 and IL-4 in cultures HUVEC. Tissue factor was assayed by procoagulant activity 
assay and GM-CSF and VCAM-1 were detected by sensitive ELISA. Y-axis scales vary for each graph. Dose-response curves for IL-1 and IL-4 
are shown for 4, 24 and 48 h after stimulation. Error bars represent 2 S.D. of the mean. 
taining the VCAM-1 xB sites. As shown in Fig. 2, both high 
and low concentrations of IL-1 induced nuclear proteins which 
specifically bound to the VCAM-1 xB motifs. In contrast, 
xB-binding activity above that of unstimulated cells was not 
detected with either oligonucleotide probe using nuclear ex- 
tracts from endothelial cells stimulated with both concentra- 
tions of IL-4. Additional assays performed using an oligonucle- 
otide containing the immunoglobulin NF-lcB-binding se- 
quences also failed to demonstrate specific binding to xB se- 
quences from IL-4-stimulated HUVEC nuclear extracts (data 
not shown). The use of an Oct-1 consensus binding motif probe 
confirmed the integrity of nuclear extracts used in this assay. 
4. Discussion 
IL-4 appears to play an important role in the physiology of 
the endothelial response to inflammatory and immune-reactive 
processes. IL-4 activation of endothelium ay contribute to the 
recruitment of eosinophils and mononuclear leukocytes in 
chronic inflammatory diseases ranging from asthma to athero- 
sclerosis. In contrast o activation by IL-1, TNF-~ or LPS, 
activation by IL-4 results in the expression of VCAM-1, but not 
ICAM-1 or E-selectin [2] on endothelial surfaces. This selectiv- 
ity results in the preferential adherence of eosinophils and 
mononuclear leukocytes rather than neutrophils. Other fea- 
tures of the inflammatory response produced by IL-1 and 
TNF-~, such as induction of procoagulant activity [1] and se- 
cretion of GM-CSF, were not observed with IL-4. 
In this study, we investigated the basis of IL-4 induction of 
VCAM-1 expression in HUVEC. While many reports have 
detailed mechanisms of HUVEC gene regulation following 
stimulation with IL-1, TNF-c~ and LPS, there have been fewer 
reports on the effects of IL-4. By demonstrating synergy of IL- 1 
and IL-4 in VCAM-1 induction, studies by Thornhill [1,8] and 
by Masinovsky [7] suggested that the IL-4 regulatory pathway 
may be distinct. Additional studies have reported that IL-4 
modulated the expression of endothelial cell inflammatory 
genes induced by IL-1. For example, while IL-4 downregulates 
the IL-l-mediated induction of tissue factor [1], it counters the 
IL-1 downregulation of thrombomodulin [31]. More recent 
studies by Kapiotis [32] show that coincubation of HUVEC 
with pyrogens (IL-I, TNF-~ or bacterial lipopolysaccharide) 
and IL-4 differentially modulated the expression of endothelial 
cell adhesion molecules. While this combination of cytokines 
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:ig. 2. EMSAs of VCAM-l xB motifs with HUVEC nuclear extracts. 
,ane numbers correspond to HUVEC nuclear extracts stimulated 
ruder the following conditions: 1,6) unstimulated; 2,7) IL-I 0.5 U/ml 
or 4 h; 3,8) IL-4 500 U/ml for 4 h; 4,9) IL-1 0.5 U/ml for 24 h; 5,10) 
L-4 500 U/ml for 24 h. Reactions in lanes 6 10 also contain unlabeled 
mmunoglobulin xB motifs at a 50-fold relative concentration as a 
:ompetitor. B, specifically binding shifted band; NS, non-specific 
~ands; F, free probe. 
:lid not affect the expression of ELAM-I in their study, a 
downregulation of 1CAM-I expression and and an enhance- 
ment of VCAM-1 expression was reported. The comparison of 
VCAM-I, GM-CSF and tissue factor in the present study is 
thus representative of the different sets of genes induced in each 
of the induced phenotypes. Whereas tissue factor, GM-CSF 
and VCAM-1 are all induced by IL-1, only VCAM-I is induced 
by IL-4. Moreover, our results how that there are differences 
in both the magnitude and duration of VCAM-1 expression 
after IL-1 and IL-4 stimulation of HUVEC. In general, the time 
course of VCAM-I gene expression induced by IL-4 can be 
characterized bya later and more sustained induction than that 
induced by IL-1. In contrast, a higher peak fold induction of 
VCAM-I protein is seen after IL-1 stimulation. By ELISA, 
VCAM-1 cell-surface protein expression progressively in- 
creased over the 48 h of the time course studied at all concen- 
trations of IL-4. Together, these findings point to an IL-4 
regulatory pathway that is at least partly independent of that 
employed by IL-1. Because IL-4 stimulation of HUVEC gives 
rise to a select repertoire of inflammatory proteins, these mech- 
anisms must be mediated by relatively restricted signals rather 
than by global cellular processes. 
Previous studies by Iademarco et al. have investigated the 
mechanisms of IL-4-induced VCAM-1 expression [14]. They 
concluded that in contrast o the transcriptional ctivation in- 
duced by TNF-c~, IL-4 increased mRNA stability but failed to 
show appreciable reporter gene activity. However, only very 
low levels of VCAM-1 were detected on endothelial cells stim- 
ulated for up to 72 h in that study. In contrast, while our ELISA 
studies did not extend beyond 48 h, high level expression was 
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detected and VCAM-1 levels continued to increase throughout 
the time course of our study. The difference in VCAM-1 cell- 
surface xpression i  the two studies may reflect differences in 
tissue culture conditions which could account for the differ- 
ences in transcriptional ctivity reported in the present study. 
Endothelial cells in culture are known to lose their ability to 
express proteins under select conditions or with serial passage, 
such as seen with P-selectin (J. Harlan, pers. commun.). In 
addition, compared with the WTCAT construct used in the 
present study, the 2180VCAMCAT reporter construct used in 
the studies of Iademarco contained additional upstream flank- 
ing sequences. Differences in transcriptional ctivity might also 
be due to the presence of cis-acting elements in the larger 
reporter construct which downmodulate he transcriptional c- 
tivity mediated by our WTCAT promoter sequences. Despite 
these arguments, however, it is clear that transcriptional effects 
do not completely explain the mechanism of IL-4-mediated 
induction of VCAM-1 in HUVEC. Other mechanisms, uch as 
the transcriptional contribution of other upstream cis-acting 
sequences, or the influence of posttranscriptional effects on 
VCAM-I mRNA, may complete the pathway of VCAM-1 in- 
duction by IL-4. 
The reporter gene data suggests that, while NF-xB is not 
required for VCAM-1 induction by IL-4, it is still important in 
the constitutive xpression of the promoler. One explanation 
for the latter finding may be that nuclear proteins bind to xB 
sequences in the absence of cell stimulation and that these 
transcription factors modulate the constitutive xpression of 
the gene. Constitutive xpression of xB-binding proteins has 
been previously reported for TNF-~ production in quiescent 
macrophages [33]. We report similar findings here for the 
VCAM-I gene. However, examination of our reporter gene 
results how that the IL-4-stimulated transcriptional ctivity of 
the xB mutant is lower than that of the wild-type construct. 
This implies that factors occupying the VCAM xB complex are 
necessary for full IL-4-induced expression of the gene. At least 
four distinct proteins have been shown to bind to xB sequences, 
in both homo- and heterodimeric configurations [34]. DNA- 
protein crosslinking studies, cotransfection experiments with 
specific xB family members and antisense oligonucleotide inhi- 
bition experiments will help to identify the transcription factors 
mediating this effect more precisely. 
Our results demonstrate that transcriptional response le- 
ments for IL-I and IL-4 lie within 289 bp from the CAP site 
of the VCAM-I gene. The reporter gene assays how that these 
elements support a 1.4- to 2.4-fold increase in promoter activity 
in response to cytokine stimulation. While this study found at 
least one of the IL-1 response lements to be xB, IL-4 induction 
of the mutant cB construct implies that an IL-4 response le- 
ment lies outside of the tcB motifs of VCAM-I. The EMSA 
studies performed in this report support our conclusions that 
NF-xB is not induced in IL-4-stimulated endothelial cells. Iade- 
marco [14] also noted that immunolabeling experiments did not 
show differences in either the level or the localization of NF-xB 
or rel family members after IL-4 stimulation. Thus, these results 
begin to unravel the molecular basis for the synergistic induc- 
tion of VCAM-1 protein expression on HUVEC observed with 
low concentrations of IL-4 and IL-1 [7,8]. 
Finally, although it is clear that the use of a truncation 
construct of the VCAM-1 promoter is artificial, we feel that our 
observations remain valid as these proximal sequences retain 
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functional activity consonant with the endogenous gene, dem- 
onstrating responsiveness to both IL-I and IL-4. Furthermore, 
this construct confers tissue specificity as transfection i to lym- 
phocyte cell lines generated no basal or induced CAT activity 
(data not shown). Additionally, previously published func- 
tional analyses of the VCAM- 1 promoter using constructs con- 
taining additional upstream sequences failed to demonstrate 
augmented basal or IL-l-stimulated promoter activity 
[13,16,17]. Induction of VCAM-1 protein expression on 
HUVEC by IL-4 appears to be an NF-xB-independent process. 
In contrast, full expression of VCAM-1 in response to inflam- 
matory cytokines requires intact xB sequences. These findings 
suggest that a non-xB regulatory pathway acts in concert with 
xB to induce VCAM-I. Although the inflammatory response 
is likely due to the combined action ofcytokines, understanding 
the activation mechanisms of each individual stimulus is neces- 
sary groundwork for studying coordinate induction. Future 
studies will be directed at the identification of the IL-4-respon- 
sive elements in the VCAM-I which are responsible for the 
transcriptional upregulation of VCAM-I gene expression in- 
duced by 1L-4. Given the participation of IL-4 in the promotion 
of atopic processes [35] and the potential role of VCAM-! in 
the recruitment of eosinophils in allergic reactions [36], a better 
definition of the molecular pathways involved in IL-4 induction 
of VCAM-1 may yield insights into the pathophysiology of
allergic conditions. 
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